Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bragonier, R.
Right arrow Articles by Brown, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bragonier, R.
Right arrow Articles by Brown, N. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 42, 103-106, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis

R Bragonier and NM Brown
Bristol Royal Hospital for Sick Children, St Michael's Hill, UK.

The pharmacokinetics and toxicity of once-daily intravenous tobramycin were studied prospectively in seven children with cystic fibrosis. Mean 1 h post-dose concentrations of 21.9 mg/L (S.D. 3.0) and 40.2 mg/L (S.D. 8.1) were achieved following tobramycin doses of 8 mg/kg and 15 mg/kg, respectively. The half-life (mean 2.3 h) was unchanged at the two doses, as were the total clearance and volume of distribution. All patients responded well to therapy. No nephrotoxicity occurred, but one patient showed transient ototoxicity.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
O. Burkhardt, C. Lehmann, R. Madabushi, V. Kumar, H. Derendorf, and T. Welte
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
J. Antimicrob. Chemother., October 1, 2006; 58(4): 822 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. H.-V. Tan, M. Mulheran, A. J. Knox, and A. R. Smyth
Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 819 - 823.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Aminimanizani, P. M. Beringer, J. Kang, L. Tsang, R. W. Jelliffe, and B. J. Shapiro
Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis
J. Antimicrob. Chemother., October 1, 2002; 50(4): 553 - 559.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Whitehead, S.P. Conway, C. Etherington, N.A. Caldwell, N. Setchfield, and S. Bogle
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Eur. Respir. J., February 1, 2002; 19(2): 303 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
C. A. Robinson and R. J. Kuhn
Management of Pulmonary Disease in Patients with Cystic Fibrosis
Journal of Pharmacy Practice, June 1, 2001; 14(3): 207 - 227.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.